- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02943473
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma
The purpose of this research study is to test whether the drug ibrutinib (trademark name: IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who currently have smoldering myeloma. The researchers conducting this trial) have reason to believe that ibrutinib can delay the development of multiple myeloma, thus giving people who currently have smoldering myeloma a longer period of time when they feel healthy and well.
Smoldering myeloma is an abnormal condition that is considered to be an early phase of the disease multiple myeloma. In this disorder, there is an abnormal growth of plasma cells, which is a type of blood cell found in the bone marrow. This growth is not as severe in people with smoldering myeloma as it is in multiple myeloma, so people with smoldering myeloma do not have any symptoms and tend to feel well. However, they have a higher risk of developing multiple myeloma than people in the general population.
Some people with smoldering myeloma are at an especially high risk of developing myeloma - 50% of these people will develop multiple myeloma 2 years after they are diagnosed with smoldering myeloma. The investigators identify these people by looking at the amount of myeloma in the bone marrow (called "bone marrow plasma cell percentage") and the amount of myeloma protein (called "serum protein electrophoresis" and "serum free light chain assay") in the blood. To be considered high risk, individuals must have highly abnormal levels for these tests.
Based upon current guidelines, people with smoldering myeloma do not require any treatment. However, known is that many of these people will develop multiple myeloma in the near future. Currently there have been no proven and effective way of preventing these people from developing multiple myeloma, which remains an incurable disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 2, open-label, single center, prospective pilot study designed to assess the efficacy of ibrutinib in subjects with high risk smoldering multiple myeloma.
All enrolled subjects will be treated with ibrutinib 560 mg (4 capsules, each containing 140 mg) taken PO daily for 12 cycles (28 days each). If a subject demonstrates benefit from ibrutinib, therapy may be extended beyond 12 cycles to a maximum of 2 years. Subjects who progress and meet criteria for symptomatic multiple myeloma will be withdrawn from study.
An initial cohort of 15 subjects will be accrued. If 4 or more patients progress to symptomatic myeloma in one year, then the study will be reviewed with the FDA to determine whether to employ a higher dose of ibrutinib, or to stop for futility. Otherwise, 21 additional patients will be accrued for a total sample size of 36.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria Disease Related
High risk SMM, defined as follows by Mayo Clinic criteria:
- Bone marrow plasma cells between 10% and 60%
- Serum M-protein ≥ 3 g/dL [except IgA ≥ 2 g/dL] or urine M-protein > 500 mg per 24 hours
- Serum free light chain ratio < 0.126 or > 8; an involved to uninvolved ratio of ≥ 100 is permitted
- Measurable disease, defined as: M-protein ≥ 1 g/dL OR Bence-Jones protein (BJP) > 200 mg/24 hr OR involved free light chain > 100 mg/dL
- Diagnosed with SMM within the last 4 years
Laboratory
Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening, with the exception of pegylated G-CSF (pegfilgrastim) and darbopoetin which require at least 14 days prior to screening defined as:
- Absolute neutrophil count > 750 cells/mm3 (1.0 x 109/L).
- Platelet count > 75,000 cells/mm3 (75 x 109/L).
Adequate hepatic and renal function defined as:
- Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN).
- Estimated creatinine clearance ≥ 30 ml/min (Cockcroft-Gault)
- Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, in which case the total bilirubin should be < 3 x ULN)
PT/INR < 1.5 x ULN and PTT (aPTT) < 1.5 x ULN
Demographic
- Men and women ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status of < 2
Exclusion Criteria Disease-Related
No end organ damage attributable to a plasma cell disorder, defined as having ANY of the following:
- Hypercalcemia: Serum calcium > 1 mg/dL above the upper limit of normal or > 11 mg/dL
- Renal insufficiency: Serum creatinine > 2 mg/dL or creatinine clearance < 30 mL per min
- Anemia: Hemoglobin value > 2 g/dL below the upper limit of normal or a hemoglobin value < 10 g/dL
- Bone lesions: One or more lytic lesions on skeletal radiography, CT, MRI, PET-CT, or PET-MRI
- Bone marrow plasma cells < 10% or > 60%
- Has received prior anti-myeloma therapy of any type
- Has received prior bisphosphonate therapy
- Has received an investigational drug, investigational vaccine, or has used an investigational medical device within 4 weeks or 4 half-lives, whichever is longer, before Cycle 1, Day 1 of study therapy
- Osteoporosis, defined as having a T-score on DEXA of ≤ -2.5
Concurrent Conditions
History of other malignancies, except:
- Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated carcinoma in situ without evidence of disease
- Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc). Any use of corticosteroids EITHER for > 14 days OR at dosages > 20 mg/day of prednisone or equivalent is prohibited.
- Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
- Recent infection requiring systemic treatment that was completed ≤ 14 days before the first dose of study drug
- Known bleeding disorders (eg, von Willebrand's disease) or hemophilia
- History of stroke or intracranial hemorrhage within 6 months prior to enrollment
- Known HIV, HCV or HBV infection. Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
- Any uncontrolled active systemic infection
- Major surgery within 4 weeks of first dose of study drug
- Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators' opinion, could compromise the subject's safety or put the study outcomes at undue risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibrutinib
Ibrutinib (trademark name is IMBRUVICA®).
560 mg dose administered on a continuous basis
|
Ibrutinib is a type of drug called a "kinase inhibitor."
Kinases are proteins inside cells that help cells live and grow.
Ibrutinib blocks a specific kinase protein in our bodies.
This protein is thought to be very important in helping blood cancer cells live and grow.
By blocking this kinase protein, ibrutinib stops cancer cells from growing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients Without Symptomatic Myeloma
Time Frame: up to 1 year
|
Disease response - the proportion of patients with high risk smoldering multiple myeloma who do not progress to symptomatic myeloma as defined by the IMWG.
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: up to 1 year
|
Overall response rate, defined as partial response or better per IMWG criteria.
(IMWG response criteria are - Complete Response, Very good partial response, partial response, Minimal response, stable disease, and progressive disease)
|
up to 1 year
|
Bone Density Changes
Time Frame: baseline and one year
|
Changes in bone density, particularly in patients with osteopenia (defined as T-score on bone densitometry testing (DEXA) of -1 to -2.5).
|
baseline and one year
|
PET-MRI Changes
Time Frame: baseline and one year
|
Changes in PET-MRI, particularly in patients with osteopenia
|
baseline and one year
|
Change in Serum Interleukin-6 (IL-6)
Time Frame: baseline and up to one year
|
Bone Related Biomarker Changes
|
baseline and up to one year
|
Change in Serum Stromal Cell-derived Factor-1 (SDF-1)
Time Frame: baseline and up to one year
|
Bone Related Biomarker Changes
|
baseline and up to one year
|
Change in Serum Receptor Activator of Nuclear-factor Kappa B Ligand (RANKL)
Time Frame: baseline and up to one year
|
Bone Related Biomarker Changes
|
baseline and up to one year
|
Change in Serum Macrophage Inflammatory Protein-1α (MIP-1α)
Time Frame: baseline and up to one year
|
Bone Related Biomarker Changes
|
baseline and up to one year
|
Change in Serum Dickkopf-1 (DKK-1)
Time Frame: baseline and up to one year
|
Bone Related Biomarker Changes
|
baseline and up to one year
|
Change in Serum C-terminal Telopeptide (CTX)
Time Frame: baseline and up to one year
|
Bone Related Biomarker Changes
|
baseline and up to one year
|
Change in Urine N-terminal Telopeptide (NTx)
Time Frame: baseline and up to one year
|
Bone Related Biomarker Changes
|
baseline and up to one year
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Precancerous Conditions
- Hypergammaglobulinemia
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Smoldering Multiple Myeloma
Other Study ID Numbers
- GCO 16-1867
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High Risk Smoldering Multiple Myeloma
-
Omar Nadeem, MDJanssen, LPRecruitingMultiple Myeloma | High-risk Smoldering Multiple MyelomaUnited States
-
Janssen Research & Development, LLCCompletedHigh-risk Smoldering Multiple MyelomaUnited States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
-
Irene Ghobrial, MDJanssen Research & Development, LLCRecruitingMultiple Myeloma | Smoldering Multiple Myeloma | High-risk Smoldering Multiple MyelomaUnited States
-
Memorial Sloan Kettering Cancer CenterMillennium Pharmaceuticals, Inc.Active, not recruitingMultiple Myeloma | High Risk Smoldering Multiple MyelomaUnited States
-
Memorial Sloan Kettering Cancer CenterHealthTree FoundationRecruitingMultiple Myeloma, SmolderingUnited States
-
Regeneron PharmaceuticalsRecruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingSmoldering Plasma Cell MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingSmoldering Plasma Cell MyelomaUnited States
-
Carl Ola Landgren, MD, PhDJanssen Scientific Affairs, LLCRecruitingMultiple MyelomaUnited States
-
University of UtahMillennium Pharmaceuticals, Inc.TerminatedCancer | Multiple Myeloma | MyelomaUnited States
Clinical Trials on Ibrutinib
-
Christian BuskeAmgen; Janssen, LPRecruitingWaldenstrom MacroglobulinemiaAustria, Germany, Greece
-
TG Therapeutics, Inc.CompletedMantle Cell Lymphoma | Chronic Lymphocytic LeukemiaUnited States
-
Johnson & Johnson Private LimitedCompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellIndia
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
The Lymphoma Academic Research OrganisationJanssen Pharmaceutica N.V., BelgiumTerminatedB-cell LymphomaFrance, Belgium
-
Pharmacyclics Switzerland GmbHJanssen Biotech, Inc., including Johnson & JohnsonEnrolling by invitationLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host DiseaseUnited States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
-
Janssen-Cilag Ltd.CompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellFrance
-
The Lymphoma Academic Research OrganisationCompletedIntraocular Lymphoma | Primary Central Nervous LymphomaFrance
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedChronic Lymphocytic LeukemiaItaly